Development of Biomarker-Driven Targeted Therapies in Cancers
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: closed (10 February 2023) | Viewed by 6061
Special Issue Editor
Interests: gastrointestinal cancers; drug development; hepatocellular carcinoma; pancreatic adenocarcinoma; biomarkers
Special Issue Information
Dear Colleagues,
We are pleased to invite you to submit articles to our Special Edition entitled “Biomarker-Driven Targeted Therapies in Cancers”. Significant progress has been made in recent decades for certain cancer types where specific molecular alterations drive cancer progression. The development of imatinib targeting BCR-ABL, c-KIT, and PDGFRA revolutionized the treatment of chronic myeloid leukemia and GIST and paved the way for modern targeted therapies. As a result of biomarker-driven targeted therapies, the prognosis of malignancies such as HER-2 positive breast cancers and BRAF-mutated melanoma has improved greatly. However, elucidating signaling networks for many other malignancies has been more challenging, with constellations of signaling pathways often being involved, making the development of targeted therapies more difficult for certain tumors. Thus, a multi-pronged targeted approach may be needed with exploration of targets beyond those found by next-generation sequencing.
This Special Issue aims to describe current research surrounding the development of the next generation of biomarker-driven targeted therapies for cancer.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- New strategies to target known driver biomarkers
- New drugs for new targets in cancer
- Novel targets
- Circulating tumor DNA as a target
- Assessing response to targeted therapies
- Challenges in dosing targeted therapies
We look forward to receiving your contributions.
Dr. Anne Mary Noonan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Novel molecular profiling
- Drug design
- Microenvironment
- Antibody–drug conjugates
- In vitro study
- In vivo study
- Genetic mutations
- Predictive markers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.